v3.25.2
Net Loss per Share - Summary of Basic and diluted net loss per share attributable to common stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Numerator:                
Net loss $ (7,585) $ (6,077) $ (6,259) $ (22,314) $ (13,662) $ (28,573) $ (36,568) $ (21,148)
Less: accretion of Preferred Stock 3,149   2,908   6,200 5,759    
Basic Net loss attributable to common stockholders (10,734)   (9,167)   (19,862) (34,332) $ (48,384) $ (32,038)
Diluted Net loss attributable to common stockholders $ (10,734)   $ (9,167)   $ (19,862) $ (34,332)    
Denominator:                
Weighted-average 1,411,649   980,803   1,410,811 980,803 1,194,172 [1] 979,098 [1]
Basic Net loss per share attributable to common stockholders $ (4.46)   $ (4.64)   $ (8.26) $ (17.38) $ (22.1) [1] $ 16.23 [1]
Diluted Net loss per share attributable to common stockholders $ (4.46)   $ (4.64)   $ (8.26) $ (17.38) $ (22.1) [1] $ 16.23 [1]
Series A Preferred Shares, as converted to ordinary [Member]                
Denominator:                
Weighted-average 994,869   994,869   994,869 994,869    
Common Stock [Member]                
Denominator:                
Basic Net loss per share attributable to common stockholders $ (4.46)   $ (4.64)   $ (8.26) $ (17.38)    
Diluted Net loss per share attributable to common stockholders (4.46)   (4.64)   (8.26) (17.38)    
Preferred Stock [Member] | Series A Preferred Shares, as converted to ordinary [Member]                
Denominator:                
Basic Net loss per share attributable to common stockholders (4.46)   (4.64)   (8.26) (17.38)    
Diluted Net loss per share attributable to common stockholders $ (4.46)   $ (4.64)   $ (8.26) $ (17.38)    
[1] The loss per share and weighted average shares used to compute basic and diluted loss per share for both 2023 and 2024 have been adjusted to reflect the recapitalization of the Company resulting from the Merger with Ikena Oncology, Inc. See Note 2 for further details.